Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

OPDIVO QVANTIG: unresectable metastatic Melanoma after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma following treatment with intravenous nivolumab and ipilimumab combination therapy.

Broader topic: Childhood Melanoma

Source population
pediatric
Disease extent
metastatic
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
unresectable
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      following treatment with intravenous nivolumab and ipilimumab combination therapy
      status
      required
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for OPDIVO QVANTIG (product label). Only dimensions stated in that wording are part of this definition.
    source wording
    OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma following treatment with intravenous nivolumab and ipilimumab combination therapy.

    Study evidence for this setting

    0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice